The VigilTM Vaccine -a bi-shRNA furin and GMCSF Autologous tumor Cell Vaccine- has reached phase II clinical trials in ovarian cancer (NCT01309230), advanced melanoma (NCT01453361), and colorectal carcinoma with liver metastases (NCT01505166). The gene discussed is FURIN; the disease is ovarian cancer.